Literature DB >> 31618297

Effects of a high-intensity pulmonary rehabilitation program on the minute ventilation/carbon dioxide output slope during exercise in a cohort of patients with COPD undergoing lung resection for non-small cell lung cancer.

Fabio Perrotta1, Antonio Cennamo2, Francesco Saverio Cerqua2, Francesco Stefanelli3, Andrea Bianco2, Salvatore Musella3, Marco Rispoli4, Rosario Salvi5, Ilemando Meoli3.   

Abstract

OBJECTIVE: Preoperative functional evaluation is central to optimizing the identification of patients with non-small cell lung cancer (NSCLC) who are candidates for surgery. The minute ventilation/carbon dioxide output (VE/VCO2) slope has proven to be a predictor of surgical complications and mortality. Pulmonary rehabilitation programs (PRPs) could influence short-term outcomes in patients with COPD undergoing lung resection. Our objective was to evaluate the effects of a PRP on the VE/VCO2 slope in a cohort of patients with COPD undergoing lung resection for NSCLC.
METHODS: We retrospectively evaluated 25 consecutive patients with COPD participating in a three-week high-intensity PRP prior to undergoing lung surgery for NSCLC, between December of 2015 and January of 2017. Patients underwent complete functional assessment, including spirometry, DLCO measurement, and cardiopulmonary exercise testing.
RESULTS: There were no significant differences between the mean pre- and post-PRP values (% of predicted) for FEV1 (61.5 ± 22.0% vs. 62.0 ± 21.1%) and DLCO (67.2 ± 18.1% vs. 67.5 ± 13.2%). Conversely, there were significant improvements in the mean peak oxygen uptake (from 14.7 ± 2.5 to 18.2 ± 2.7 mL/kg per min; p < 0.001) and VE/VCO2 slope (from 32.0 ± 2.8 to 30.1 ± 4.0; p < 0.01).
CONCLUSIONS: Our results indicate that a high-intensity PRP can improve ventilatory efficiency in patients with COPD undergoing lung resection for NSCLC. Further comprehensive prospective studies are required to corroborate these preliminary results.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31618297     DOI: 10.1590/1806-3713/e20180132

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  6 in total

1.  Implications of the Adiponectin System in Non-Small Cell Lung Cancer Patients: A Case-Control Study.

Authors:  Ersilia Nigro; Fabio Perrotta; Maria Ludovica Monaco; Rita Polito; Pia Clara Pafundi; Maria Gabriella Matera; Aurora Daniele; Andrea Bianco
Journal:  Biomolecules       Date:  2020-06-18

Review 2.  COVID-19 and the elderly: insights into pathogenesis and clinical decision-making.

Authors:  Fabio Perrotta; Graziamaria Corbi; Grazia Mazzeo; Matilde Boccia; Luigi Aronne; Vito D'Agnano; Klara Komici; Gennaro Mazzarella; Roberto Parrella; Andrea Bianco
Journal:  Aging Clin Exp Res       Date:  2020-06-16       Impact factor: 3.636

3.  Intercept of minute ventilation versus carbon dioxide output relationship as an index of ventilatory inefficiency in chronic obstructive pulmonary disease.

Authors:  Fang Lin; Shan Nie; Ranran Zhao; Min Cao; Wei Yuan; Yunxiao Li; Chunting Tan; Bo Xu; Haoyan Wang
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

Review 4.  Ventilatory efficiency slope is associated with cardiopulmonary complications after thoracoscopic anatomical lung resection.

Authors:  Benoît Bédat; Evangelos Koliakos; Marco S Demarchi; Jean Perentes; Marc-Joseph Licker; Frédéric Triponez; Thorsten Krueger; Wolfram Karenovics; Michel Gonzalez
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

5.  Pulmonary rehabilitation: various diseases, many approaches, and multiple questions.

Authors:  Paulo José Zimermann Teixeira; Simone Bernardes; Marcelo Nogueira
Journal:  J Bras Pneumol       Date:  2019-12-09       Impact factor: 2.624

Review 6.  Food, Nutrition, Physical Activity and Microbiota: Which Impact on Lung Cancer?

Authors:  Ersilia Nigro; Fabio Perrotta; Filippo Scialò; Vito D'Agnano; Marta Mallardo; Andrea Bianco; Aurora Daniele
Journal:  Int J Environ Res Public Health       Date:  2021-03-01       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.